Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2014-08-28 Annual Report
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
Appendix 4E and Preliminary Final Report 61 pages 415.7KB
Annual Report Classification · 100% confidence The document is titled 'Cellmid Limited Appendix 4E Preliminary final report' and covers the financial year ended 30 June 2014. It includes detailed financial statements, directors' report, audit report, corporate governance statement, and notes to the financial statements. The content includes comprehensive financial data, operating results, review of operations, and detailed disclosures typical of a full annual report. The presence of audited financial statements and extensive narrative confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2014
2014-08-28 English
Date of Annual General Meeting 1 page 54.8KB
AGM Information Classification · 100% confidence The document is an ASX announcement regarding the date of the company's next Annual General Meeting (AGM). It specifies the meeting date and references compliance with ASX Listing Rules and the company's constitution. There is no financial data, no detailed report content, and the document is relatively short (2133 characters). It is clearly an announcement about the AGM date, not the AGM materials themselves or any other report. Therefore, the appropriate classification is AGM Information (AGM-R).
2014-08-19 English
Cellmid Newsletter 8 pages 1.5MB
Regulatory Filings Classification · 85% confidence The document is a detailed newsletter from August 2014, containing a message from the CEO, operational updates, scientific study summaries, and business progress reports. It discusses financial results, clinical programs, product development, market strategies, and licensing updates. The content is narrative and informative, focusing on business and scientific progress rather than formal financial statements or regulatory disclosures. It does not contain formal financial statements, audit opinions, voting results, or legal proceedings. It is not a transcript of a call, nor a presentation slide deck. The document is longer than 5,000 characters and provides substantive company updates, but it is not an official annual or interim report. It is best classified as a general company newsletter or update, which does not fit neatly into the more formal categories. Given the fallback rule, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and company update that does not fit other specific categories.
2014-08-17 English
Cleansing Notice and Appendix 3B 10 pages 712.0KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement titled 'Notice under section 708A(5)(e) of the Corporations Act' related to the issue of securities by Cellmid Limited. It includes detailed information about the securities issued, the purpose of the issue (endorsement services), and an Appendix 3B form which is a standard form for new issue announcements and applications for quotation of additional securities on the ASX. The content focuses on the issuance of shares and compliance with relevant securities laws, without any financial statements, earnings data, or management discussion. This type of document is a capital/financing update regarding new share issuance and related regulatory compliance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance information, confirming it is not a mere announcement of a report or a certification, but a substantive filing about capital changes.
2014-08-14 English
Appendix 4C - quarterly 6 pages 95.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 July 2014 from Cellmid Limited providing comments related to an attached Appendix 4C form. Appendix 4C is a quarterly report for entities admitted on the basis of commitments, which includes detailed cash flow statements, payments to directors, financing facilities, and compliance statements. The document contains substantive financial data and analysis for the quarter ended 30 June 2014, including operating, investing, and financing cash flows, as well as notes explaining the financial activities. The presence of detailed quarterly financial data and the nature of the Appendix 4C form indicate this is a quarterly financial report rather than a simple announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2014
2014-07-28 English
Cellmid Granted UK Patent for Use of Midkine for Hair Growth 2 pages 31.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement regarding the granting of a UK patent for the use of midkine for hair growth. It details the patent's scope, protection period, and the company's related business activities. There is no financial data, regulatory certification, or report publication mentioned. The content is a corporate announcement about intellectual property rights and business development, not a financial report or regulatory filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2014-07-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.